<DOC>
	<DOCNO>NCT00371826</DOCNO>
	<brief_summary>The aim study assess safety efficacy corticosteroid discontinuation versus cyclosporine micro emulsion discontinuation recipient receive reduced exposure cyclosporine micro emulsion corticosteroid plus enteric-coated mycophenolate sodium ( EC-MPS ) initially , change everolimus 2 week post-transplant . These two group compare third control group , receive treatment consist cyclosporine micro emulsion , enteric-coated mycophenolate sodium ( EC-MPS ) steroid .</brief_summary>
	<brief_title>SOCRATES : Steroid Cyclosporine Removal After Transplantation Using Everolimus</brief_title>
	<detailed_description />
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Inclusion criterion 1 . Males female age 1865 year inclusive . 2 . First time recipient cadaveric , live unrelated living relate donor kidney transplant . 3 . Patients willing able participate study write informed consent obtain . Exclusion criteria 1 . Patients recipients multiple organ transplant , include one kidney , kidney pancreas , previous transplant organ kidney . 2 . Patients high immunological risk graft loss , indicate peak PRA &gt; 50 % loss previous renal allograft within first 6 month transplantation due acute rejection . 3 . Patients receive investigational drug within 4 week prior screen visit . 4 . Presence severe allergy hypersensitivity drug similar everolimus ( e.g . antibiotic Clindamycin ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Renal transplantation</keyword>
	<keyword>everolimus</keyword>
	<keyword>Immunosuppressants</keyword>
</DOC>